This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects:

Pharmacology This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles ??? This article has not yet received a rating on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Otamixaban. PubMed provides review articles from the past five years (limit to free review articles) The TRIP database provides clinical publications about evidence-based medicine. Other potential sources include: Centre for Reviews and Dissemination and CDC

doi: 10.1016/S0140-6736(09)61454-9 - head to head with UFH & 2b3a (eptifibatide). This was mainly an efficacy/safety study, and the abstract suggests that phase III trials will probably happen now. I'm not entirely sure why one would use an intravenous anticoagulant rather than LMWH, and nor am I clear why this phase II trial went into the Lancet. But there we are, and it is probably notable enough to be discussed here. JFW |  T@lk 11:06, 6 September 2009 (UTC) reply